Ad hoc: Interim report about clinical trial of BF-200 ALA in,actinic keratosis ( LEVERKUSEN Germany 30 April 2007

Ad hoc: Interim report about clinical trial of BF-200 ALA in,actinic keratosis

LEVERKUSEN, Germany, 30 April 2007 - Biofrontera AG announced that an interim report regarding the clinical study of BF-200 ALA in actinic keratosis was received today from an independent review committee. The objectives of the study are to investigate the efficacy and safety of several doses of BF-200 ALA in photodynamic therapy. The comments received today refer to the clinical results eight weeks after treatment. An additional report about the results after twelve weeks will follow.

The interim committee reported that no side effect justifying concerns about the safety of this dose were observed in any dose group. On the basis of the available data, the therapy was found to be safe for all doses tested.

In spite of the limited patient number, different doses gave rise to clear differences in efficacy. However, the results of the different doses were not yet disclosed. The committee announced this disclosure once it has received and analyzed the clinical results 12 weeks after treatment. Biofrontera expects this second report within few weeks.

To optimize the statistical study design, the committee has proposed to continue the phase III part of the study separately. This will enable the complete analysis of the 12-week data. On this basis, Biofrontera intends to continue the further development of the 10 % dose, provided this dose selection is supported by the 12-week data.

Biofrontera AG Hemmelrather Weg 201, 51377 Leverkusen, Germany ISIN: DE0006046113 WKN: 604611

Contact: Anke zur Mühlen Biofrontera AG Tel.: +49 (0214) 87 63 222 Fax.: +49 (0214) 87 63 290 e-mail: a.zurmuehlen@biofrontera.com

Post Your Comments:

(Date:8/18/2008)...- Oramed,Pharmaceuticals, I...developer,of oral delivery systems, announced toda... Assess the Safety, Pharmacokinetics (PK) and,Phar...s in Healthy,Subjects," has been chosen for presen...European Association for the Study of Diabetes (EA...

(Date:8/17/2008)...nhua-- Pharmaxis,(ASX: PXS;...tal Phase 3,clinical trial of Bronchitol for the t...t., The first efficacy data from the trial is exp...9. The trial commenced its dosing phase in,April 2... subjects in June,2008 and closed today with 325 s...

(Date:8/14/2008)...BiTE) showing clinical benefit in cancer,patients;...gnize and attack canc...tCall/ -- Micromet, Inc.,(Nasdaq: MITI ), a bioph...,antibodies for the treatment of cancer, inflammat...cation of a Phase 1 clinical study(1) on its,BiTE(...

(Date:8/13/2008)...irstCall/ -- As biotechnology,pharmaceutical and ...l,trials beyond their own borders to other parts o...h America, complicated regulatory environments,cha...ing to an analysis by,Aon Corporation (NYSE: AOC ...ose companies a visual representation of the compl...

Breaking Medicine Technology:Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome) 2 Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 2 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 3 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 4 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 5 Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 6 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 2 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 3 Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders 4 Healthcare M 26A Activity on the Rise 9649 1 Healthcare M 26A Activity on the Rise 9649 2 Internet Comes to Rescue of 14 Million Uninsured in U S 3B Providing Access to Gov Health Programs Theyre Not Aware of 9645 1 Internet Comes to Rescue of 14 Million Uninsured in U S 3B Providing Access to Gov Health Programs Theyre Not Aware of 9645 2 Internet Comes to Rescue of 14 Million Uninsured in U S 3B Providing Access to Gov Health Programs Theyre Not Aware of 9645 3 New Poll 3A Only 16 25 of Californians Support Mandatory Purchase of Private Health Insurance 3B 71 25 Behind Regulation of Premium Increases 9641 1 New Poll 3A Only 16 25 of Californians Support Mandatory Purchase of Private Health Insurance 3B 71 25 Behind Regulation of Premium Increases 9641 2 Society for Biological Engineering Holds First International Conference on Stem Cell Engineering 2615 1 Society for Biological Engineering Holds First International Conference on Stem Cell Engineering 2615 2

[0] Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)[1] Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment [0] Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab [0] Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders

...ch 12, 2007: Progen Industries Limited,(ASX: PGL; ...8,Phase II liver cancer data has been accepted for...ssociation for the Study of the Liver,(EASL). Prog...er,cancer trial at the American Association for Ca...xpectation of having final data fully analysed and...

...d Safety Profile and Excellent,Pharmacokinetic Pro... 2007 /PRNewswire/ --,CeNeRx BioPharma, Inc., a cl...g innovative treatments for diseases of the centra... from a Phase I,clinical trial of Tyrima(TM), its ... anxiety. In this study, Tyrima was safe and well,...

Other Medicine Technology:PI-88 Data to be Presented at Key International Conferences 2 PI-88 Data to be Presented at Key International Conferences 3 CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 2 CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 3

PI-88 Data to be Presented at Key International Conferences CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant

(Date:8/20/2008)... CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ -- ...reported preliminary income from,continuing operat... $27.5,million, or $0.76 per diluted share, includ...r diluted share, related to provisions for store,c...a 6.8 percent increase,compared with income from c...

(Date:8/20/2008)...IELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/Chan...lness Promotion will give thousands of,Detroit met...LTHY LIVING,FOR KIDS" program. This year the progr...m. to 5 p.m. at the Charles H. Wright Museum of Af...7, "Healthy Living for Kids",has provided free imm...

(Date:8/20/2008)...N and OTTAWA, Aug. 20 /PRNewswire-FirstCall/ -- iN...nd information portal, announced,today the third w...g a free,Nintendo Wii and Wii Fit system. The Winn...n, Michigan. iNutrition sweepstakes winner Ron Mil...excited." He then told his,son who responded with,...

(Date:8/20/2008)...PRINGS, Pa., Aug. 20 /PRNewswire-USNewswire/ -- Go... agricultural industry is struggling,with high fue...ng the need,to secure the state,s energy independe...g adults., Nearly 900 guests gathered to hear the...ay Luncheon at Ag Progress Days, Pennsylvania,s,la...

[0] Longs Drug Stores Corporation Reports Second Quarter Results [0] WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History [0] Weight Loss and Fitness Information Site iNutrition.com Gives Away Third Nintendo Wii and Wii Fit [0] Pennsylvania Governor Rendell Highlights Renewable Energy, Health Care Reform at Ag Progress Days

...lips who was on his way to becoming a lawyer says ...// “The top step had ice, and I went straight over...urs, and when they found me, I had blood coming ou... recollection for two and a half years after that ...

... their risk of birth defects. Now, new research sh...e.// Researchers say about 31,000 stroke-related d...s may have been prevented each year since fortific...s homocysteine levels. People with higher homocyst...

...esearchers say the estrogen pills do not reduce th...ed risk of stroke.// Researchers say their result...or decrease the risk of heart disease as combinati...trogen also does not appear to affect a woman’s ri...

...could help fight another. Researchers say the litt...G , may hold a key to helping researchers devise n...results from the Multicenter Acquired Immunodefici...estigators followed a large group of HIV-infected ...

Other Medicine News:

New Treatment For Headache Folic Acid Found To Be Beneficial For Stroke Patients The Side Effects Of Estrogen Therapy The Possibility Of Fighting HIV with Another Virus Questioned

... national reference laboratory and a worldwide lea...ent. ARUP offers an extensive test menu of highly ...natomic pathology. Owned by the University of Utah...f of the nation's university teaching hospitals an...

Medicine Products:

Antibody Detection, RBC Antibiotic MIC/MBC Antibiotic Levels Antibiotic Level, Penicillin

( LEVERKUSEN Germany 30 April 2007 - B...)Ad hoc: Interim report about clinical trial of BF-200 ALA in,actinic keratosis,Health